Abstract 236MO
Background
Pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) is a strong prognosticator for survival in early triple negative breast cancer (TNBC). Chemotherapy is recommended for most patients with stage I TNBC with an increase in use in the neoadjuvant setting as recommended by the recent ESMO guidelines. However, the pCR rate after NACT and the prognostic value in stage 1 TNBC is largely unknown.
Methods
cT1N0M0 TNBC patients who received standard of care NACT followed by surgery between 2012 and 2022 were identified from the Netherlands Cancer Registry. Factors associated with pCR (ypT0/is, ypN0) and the association of pCR with overall survival (OS) were evaluated.
Results
We identified 1144 patients treated with anthracycline and taxane-based neoadjuvant chemotherapy, of whom 472 patients (41.3%) received a platinum-based regimen and 282 (24.7%) received adjuvant capecitabine. The median follow-up was 3.8 years. The majority of patients had a cT1c tumor (94.1%) and most tumors were ductal carcinomas (90.5%). A total of 656 patients (57.3%) had a pCR. Younger age (age <50 years versus ≥50 years; OR 1.75, 95% CI 1.36-2.26) and higher tumor grade (OR 2.07, 95% CI 1.55-2.76) were associated with a higher likelihood of pCR, while patients with a lobular carcinoma had a lower likelihood of having a pCR (OR 0.18, 95% CI 0.03-0.69). Platinum-based treatment was not significantly associated with improved pCR rates (57.1% versus 57.6% for patients not treated with platinum; p=0.9). Patients with a pCR had a better OS compared to patients with residual disease (HR 0.29, 95% CI 0.15-0.56), with a 4-year OS of 98% versus 93% for patients with and without a pCR respectively.
Conclusions
Data from this real-world nationwide Dutch registry on neoadjuvant chemotherapy for stage I TNBC demonstrates pCR to be associated with a favorable long-term outcome in stage 1 TNBC, supporting the use of NACT in this setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Siesling: Non-Financial Interests, Personal, Advisory Role: Pfizer. S. Linn: Financial Interests, Institutional, Advisory Role, Advisory role + travel/accomodations/expenses: Daiichi Sankyo; Financial Interests, Institutional, Advisory Role: AstraZeneca, IBM; Non-Financial Interests, Institutional, Advisory Role: Cergentis; Financial Interests, Institutional, Research Funding: Genentech/Roche, AstraZeneca, Tesaro, Merck, Immunomedics, Eurocept Pharmaceuticals, Agendia, Novartis. M. Kok: Financial Interests, Institutional, Research Funding: BMS, Roche, AstraZeneca; Financial Interests, Institutional, Advisory Role: AstraZeneca, Daiichi Sankyo, Domain Therapeutics, Alderaan, MSD; Financial Interests, Institutional, Advisory Role, Advisory role + invited speaker: BMS, Roche; Financial Interests, Institutional, Invited Speaker: Gilead. All other authors have declared no conflicts of interest.
Resources from the same session
233MO - Ovarian function suppression in HR-positive, HER2-positive breast cancer: An exploratory analysis from the HERA trial
Presenter: Sung Gwe Ahn
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
234MO - Explaining the relationships between age, endocrine therapy persistence and risk of recurrence in hormone-positive early breast cancer: A nationwide cohort study
Presenter: Elise Dumas
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
235MO - Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE
Presenter: Sherene Loi
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Invited Discussant 233MO, 234MO and 235MO
Presenter: Kevin Kalinsky
Session: Mini oral session: Breast cancer, early stage
Resources:
Slides
Webcast
237MO - TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy
Presenter: Miguel Martin Jimenez
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
238MO - PROMENADE: PembROlizuMab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohort
Presenter: Francois Cherifi
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA14 - Intensified alkylating chemotherapy with autologous stem cell rescue (IACT) or conventional chemotherapy followed by olaparib (CCT-O) in stage III, HER2-negative, homologous recombination deficient (HRD) breast cancer (BC): Survival results of the randomized-controlled SUBITO trial
Presenter: Sabine Linn
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Invited Discussant 236MO, 237MO, 238MO and LBA14
Presenter: Lisa Carey
Session: Mini oral session: Breast cancer, early stage
Resources:
Slides
Webcast
LBA15 - Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial
Presenter: Meghna Trivedi
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA16 - Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) in the neoadjuvant setting: Results from the I-SPY 2.2 trial
Presenter: Katia Khoury
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast